NASDAQ:SWTX SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis $49.77 -1.11 (-2.18%) Closing price 03/13/2025 04:00 PM EasternExtended Trading$49.90 +0.13 (+0.26%) As of 03/13/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About SpringWorks Therapeutics Stock (NASDAQ:SWTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SWTX alerts:Sign Up Key Stats Today's Range$48.64▼$51.5150-Day Range$32.50▼$59.9352-Week Range$28.21▼$62.00Volume1.65 million shsAverage Volume1.25 million shsMarket Capitalization$3.73 billionP/E RatioN/ADividend YieldN/APrice Target$73.20Consensus RatingBuy Company OverviewSpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.Read More… Remove Ads SpringWorks Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreSWTX MarketRank™: SpringWorks Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 474th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSpringWorks Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSpringWorks Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about SpringWorks Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($2.05) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SpringWorks Therapeutics is -14.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SpringWorks Therapeutics is -14.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpringWorks Therapeutics has a P/B Ratio of 4.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about SpringWorks Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.35% of the float of SpringWorks Therapeutics has been sold short.Short Interest Ratio / Days to CoverSpringWorks Therapeutics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SpringWorks Therapeutics has recently decreased by 21.95%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSpringWorks Therapeutics does not currently pay a dividend.Dividend GrowthSpringWorks Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.35% of the float of SpringWorks Therapeutics has been sold short.Short Interest Ratio / Days to CoverSpringWorks Therapeutics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SpringWorks Therapeutics has recently decreased by 21.95%, indicating that investor sentiment is improving significantly. News and Social Media3.9 / 5News Sentiment1.04 News SentimentSpringWorks Therapeutics has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for SpringWorks Therapeutics this week, compared to 5 articles on an average week.Search Interest10 people have searched for SWTX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows7 people have added SpringWorks Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, SpringWorks Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,402,956.00 in company stock.Percentage Held by InsidersOnly 7.61% of the stock of SpringWorks Therapeutics is held by insiders.Read more about SpringWorks Therapeutics' insider trading history. Receive SWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SWTX Stock News HeadlinesInsider Selling: SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) COO Sells 20,000 Shares of StockMarch 6, 2025 | insidertrades.comBhavesh Ashar Sells 1,016 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) StockFebruary 25, 2025 | insidertrades.comA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. March 14, 2025 | Porter & Company (Ad)Daniel Lynch Sells 400 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) StockFebruary 20, 2025 | insidertrades.comSpringWorks Shares Rise More Than 30% in 3 Months: Here's WhyMarch 12 at 6:10 PM | msn.comPeninsula biotech raises $35 million, looks to move quickly into late-stage mesothelioma trialMarch 12 at 10:18 AM | bizjournals.comSpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A BuzzMarch 11 at 9:15 AM | seekingalpha.comCheck Out What Whales Are Doing With SWTXMarch 7, 2025 | benzinga.comSee More Headlines SWTX Stock Analysis - Frequently Asked Questions How have SWTX shares performed this year? SpringWorks Therapeutics' stock was trading at $36.13 on January 1st, 2025. Since then, SWTX shares have increased by 37.8% and is now trading at $49.77. View the best growth stocks for 2025 here. How were SpringWorks Therapeutics' earnings last quarter? SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) issued its quarterly earnings data on Thursday, February, 20th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by $0.38. The company earned $61.55 million during the quarter, compared to analysts' expectations of $60.53 million. SpringWorks Therapeutics had a negative trailing twelve-month return on equity of 46.74% and a negative net margin of 134.73%. Does SpringWorks Therapeutics have any subsidiaries? SpringWorks Therapeutics subsidiaries include SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc.. When did SpringWorks Therapeutics IPO? SpringWorks Therapeutics (SWTX) raised $126 million in an initial public offering on Friday, September 13th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are SpringWorks Therapeutics' major shareholders? Top institutional investors of SpringWorks Therapeutics include FMR LLC (15.00%), Vanguard Group Inc. (9.62%), Deep Track Capital LP (4.65%) and Boxer Capital Management LLC (4.60%). Insiders that own company stock include Orbimed Advisors Llc, Saqib Islam, Badreddin Edris, Daniel Lynch, Bhavesh Ashar, Daniel Pichl and Julie Hambleton. View institutional ownership trends. How do I buy shares of SpringWorks Therapeutics? Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SpringWorks Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that SpringWorks Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings2/20/2025Today3/13/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SWTX CIK1773427 Webwww.springworkstx.com Phone203-883-9490FaxN/AEmployees230Year Founded2017Price Target and Rating Average Stock Price Target$73.20 High Stock Price Target$81.00 Low Stock Price Target$65.00 Potential Upside/Downside+47.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-325,100,000.00 Net Margins-134.73% Pretax Margin-203.09% Return on Equity-46.74% Return on Assets-41.12% Debt Debt-to-Equity RatioN/A Current Ratio6.16 Quick Ratio6.02 Sales & Book Value Annual Sales$191.59 million Price / Sales19.47 Cash FlowN/A Price / Cash FlowN/A Book Value$10.01 per share Price / Book4.97Miscellaneous Outstanding Shares74,936,000Free Float68,725,000Market Cap$3.73 billion OptionableOptionable Beta0.76 Social Links Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:SWTX) was last updated on 3/14/2025 by MarketBeat.com Staff From Our PartnersNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump Shock to change everything Is this Trump’s next major move? Millionaire trading expert Imre Gams has found a bill that directs the Uni...Centurion Publishing | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump's 100-Day Plan Triggers Global RetaliationIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredMarch 18th: Gold SHOCK?Starting March 18th, a major shift could send gold soaring — or crashing. Either way this shift goes... ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SpringWorks Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.